SCHEMBL3922845

SCHEMBL3922845

C=C(C)S(=O)(=O)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6521836 0.80
SCHEMBL27504039 0.77
SCHEMBL27516710 0.72
SCHEMBL620005 0.72
SCHEMBL13921051 0.72
SCHEMBL28248554 0.72
SCHEMBL696652 0.72
SCHEMBL3620813 0.72
SCHEMBL29059220 0.72
Methacrylic Acid SCHEMBL21835888 0.69 TDP1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4701735-A1 HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR Nested Therapeutics, Inc. (US) 2026-03-04 EP disclosed
US-20250353854-A1 FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN BIOMEA FUSION INC (US) 2025-11-20 US disclosed
US-12473285-B2 DCN-1 modulating compounds and methods of use thereof CELLARITY, INC. (US) 2025-11-18 US disclosed
US-20250289811-A1 HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 US disclosed
US-20250257063-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF THAMES PHARMA PARTNERS 2025-08-14 US disclosed
US-20250163057-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF THAMES PHARMA PARTNERS 2025-05-22 US disclosed
WO-2025096956-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF CELLARITY, INC. (US) 2025-05-08 WO disclosed
US-20250074881-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2025-03-06 US disclosed
EP-4514471-A1 HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS Nested Therapeutics, Inc. (US) 2025-03-05 EP disclosed
CN-119487021-A Heterocyclic derivatives as inhibitors of mitogen-activated protein kinase (MEK) 内斯特治疗公司 2025-02-18 CN disclosed
US-7498350-B2 Oxazolidinones as antibacterial agents ASTRAZENECA AB (SE) 2009-03-03 US disclosed
US-20080064689-A1 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents ASTRAZENECA AB (SE) 2008-03-13 US disclosed
WO-2008011072-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS, ANALOGS AND DERIVATIVES THEREOF AND USES THEREOF OSURF (OHIO STATE UNIVERSITY RESEARCH FOUNDATION) (US) 2008-01-24 WO disclosed
US-20080021071-A1 3-{4-(Pyridin-3-Yl) Phenyl}-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents ASTRAZENECA AB (SE) 2008-01-24 US disclosed
US-20080021012-A1 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents ASTRAZENECA AB (SE) 2008-01-24 US disclosed
US-20070208062-A1 3-(4-(2-DIHYDROISOXAZOL-3-YLPYRIDIN-5-YL)PHENYL)-5-TRIAZOL-1-YLMETHYLOXAZOLIDIN-2-ONE DERIVATIVES AS MAO INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2007-09-06 US disclosed
US-7199143-B2 Chemical compounds ASTRAZENECA AB (SE) 2007-04-03 US disclosed
US-7192974-B2 Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents ASTRAZENECA AB (SE) 2007-03-20 US disclosed
US-4785016-A VASOCONSTRICTION, MIGRAINES ALKANEAMINO, ALKANE SULFONAMIDE INDOLES GLAXO GROUP LIMITED (GB) 1988-11-15 US disclosed
US-4298522-A HEAT AND AGING RESISTANCE NIPPON ZEON CO. LTD. (JP) 1981-11-03 US disclosed